NeoImmuneTech(NIT) is led by a highly experienced team of scientists, clinicians and strategists, relentlessly pursuing the development of novel cancer and immune therapies.
Se Hwan Yang, Ph.D. - Co-president / Chief Executive Officer
Dr. Se Hwan Yang founded NeoImmuneTech in January 2014. Dr. Yang has created several intellectual-property protected inventions, including the hyFc® platform technology and Hyleukin-7TM drug candidate. Prior to his position at NIT, Dr. Yang was Genexine’s Head of Research Institute and Business division from 2007 to 2014 and has served as a BOD member of Genexine. He received his Ph.D. from Pohang University of Science and Technology and has over 20 years of experiences of research, product development and business in life sciences, including molecular biology, immunology and protein engineering.
Richard Kang, Ph.D. - Co-president / Chief Executive Officer
Dr. Richard Kang has served as Chief Operating Officer and Chief Financial Officer since 2015 and 2018, respectively. Dr. Kang joined NeoImmuneTech’s Board of Directors in January 2014. Dr. Kang is an active serial entrepreneur. He has served as Board of Directors and Chief Operating Officer at NeuroBo Pharmaceuticals, Inc. and has served as Board of Directors and Chief Executive Officer at JK BioPharma Solutions, Inc. Prior to diving in Bio/Pharmaceutical industry, he had been achieved scientific publications including Cell and Nature as a scientist in Genetics, Molecular and Cellular Biology and Pathology. Dr. Kang holds B.S. and M.S. from Seoul National University in Korea and Ph.D. from the University of Edinburgh in UK and was a postdoctoral visiting fellow at National Cancer Institute, NIH.
NgocDiep (“Diep”) Le, M.D., Ph.D. - Executive Vice President / Chief Medical Officer
Dr. Le joined NeoImmuneTech in October 2018 as the Chief Medical Officer (CMO). She is a trained medical oncologist with over 15 years of drug development experience across all phases of Oncology R&D, in both solid tumors and hematologic malignancies. Most recently, she served as the CMO at Verastem where she led the company’s first successful product approval. Prior to Verastem, she was the Vice President in Immuno-Oncology Innovative Medicines at MedImmune, served as Global Clinical Program Head at Novartis Oncology, and Executive Medical Director at GSK where she successfully led the clinical development program for the MEK inhibitor trametinib (MEKINISTTM) from the first-in-human study through FDA approval. Dr. Le began her industry career at Amgen, Inc. as Medical Sciences Medical Director in Early Development Oncology. She received her B.S. in Biology from the California Institute of Technology, earned her MD and PhD in Cancer Biology from Stanford University School of Medicine. She completed a Medical Oncology Fellowship at the Duke Comprehensive Cancer Center and was a faculty at Duke prior to joining biopharmaceutical industry.
Tae Woo Kim, CPA - Chief Financial Officer
Mr. Kim joined NeoImmuneTech, Inc. in May 2018 as Finance Director. His first professional career started at PricewaterhouseCoopers(PwC) Korea in 2006. For 10+ years in PwC, he was mainly involved with financial audit service for Korean listed companies as a part of Capital Market Group. Also, during his period in PwC, he also successfully completed his mission to be seconded to another PwC territory that is PwC Taiwan for three years. This made him accumulate his knowledge about Korean Capital Market and global acumen. After that, he joined Englewood Lab, a New Jersey based the third US company that is listed in KOSDAQ. His role was a CFO that is responsible for all the KOSDAQ listing related matters. Mr. Kim holds his BA in Business Administration from Korea University and acquired license from Korea Institute of Certified Public Accountant.